Biotalys EVOCA California Registration
Analysis based on 8 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
The United States — California registration removes a key regulatory hurdle for Biotalys' lead product, improving the likelihood of successful commercialization and potentially boosting investor confidence. This positive regulatory milestone may support Biotalys' stock price and enhance its competitive position in the biological crop protection market.
Biotalys, an Agricultural Technology company listed on Brussels Stock Exchange, announced on September 2, 2026, that the United States — California Department of Justice (CDPR) granted state registration for EVOCA, its first protein-based biofungicide. This approval follows a public consultation process completed in July and confirms EVOCA met United States — California's stringent regulatory requirements for human health, environmental safety, and efficacy. United States — California is recognized for having some of the world's most rigorous crop protection standards, making this approval a significant validation of Biotalys' AGROBODY platform. The registration builds on earlier approvals: the U.S. Environmental Protection Agency (EPA) approved EVOCA in December 2025, and United States — Florida granted state approval earlier in 2026. EVOCA NG, the next-generation product containing the same active ingredient, is expected to become Biotalys' first commercial biofungicide, with a planned U.S. launch in 2029 and European launch in 2030, targeting a combined market of around USD 1.1 billion. CEO Carlo Boutton highlighted that the United States — California decision strengthens confidence in bringing EVOCA NG to U.S. growers and provides shareholders greater visibility on the commercialization pathway.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard